A new study found an association between hydroxychloroquine (HCQ) use and early and long-term benefits on kidney function in people with lupus nephritis, (LN, lupus-related kidney disease). HCQ (known commercially as Plaquenil®) is safe and widely used to support more favorable outcomes in people with active disease. The therapy protects kidney function by preventing flares.
Biopsy data from a group of 209 people with LN was examined. The researchers found that 33% and 23% of the group experienced glomerular filtration rate (eGFR, a measure used to assess how well your kidneys are filtering blood) decline of ≥30% or ≥40% along with a reduction in the annual eGFR slope decline, which are early indicators of terminal events such as kidney failure.
HCQ use was linked to a 77% reduced risk of eGFR decline by ≥30% in people with stage 3 or higher chronic kidney disease. Additionally, HCQ exposure decreased the annual eGFR slope decline by 5.12 and 3.17 ml/min/1.73 m² in the first 5- and 10-years post-diagnosis, respectively.
These findings support incorporating HCQ as a crucial element of LN management protocols, not just for systemic benefits, but also for its potential to preserve kidney function. The findings underline both the immediate and long-term benefits of HCQ in slowing eGFR slope decline in LN.
These findings highlight the importance of initiating and maintaining HCQ therapy early to protect kidney health and manage disease, even if systemic lupus erythematosus is confined to the kidneys. Consult your physician before making any changes to your medication. Learn more about Hydroxychloroquine.
This post was originally published on this site